Update on Direct Oral AntiCoagulants (DOACs)

J. Koscielny; C. Rosenthal; C. von Heymann

doi:10.1055/s-0038-1657856

Phlebologie, Table of Contents

Phlebologie 2018; 47(03): 137-145
DOI: 10.1055/s-0038-1657856

Übersichtsarbeiten – Reviews

Schattauer GmbH

Update on Direct Oral AntiCoagulants (DOACs)

Perioperative “switching”, drug interactions and persistenceUpdate Direkte Orale AntiKoagulanzien (DOAKs)Perioperatives „Switching”, Medikamenteninteraktionen und Persistenz

J. Koscielny

¹Gerinnungsambulanz mit Hämophiliezentrum im ambulanten Gesundheitszentrum (AGZ), Charité Campus Mitte (CCM), Universitätsmedizin Berlin

,

C. Rosenthal

²Klinik für Anästhesiologie mit Schwerpunkt operative Intensivmedizin, Charité Campus Virchow Klinikum (CVK), Universitätsmedizin Berlin

,

C. von Heymann

³Klinik für Anästhesie, Intensivmedizin, Notfallmedizin und Schmerztherapie, Vivantes Klinikum im Friedrichshain, Berlin

› Author Affiliations

Abstract

Full Text

PDF Download

Keywords

DOACs - rivaroxaban - apixaban - edoxaban - dabigatran - “switching” - drug interactions - persistence

Schlüsselwörter

DOAKs - Rivaroxaban - Apixaban - Edoxaban - Dabigatran - „Switching” - Medikamenteninteraktionen - Persistenz

References

References
1 Healey JS, Eikelboom J, Douketis J. et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: Results from the Randomized Evaluation of Long-Term Antico-agulation Therapy (RE-LY) Randomized Trial. Circulation 2012; 126: 343-348.
2 Patel MR, Mahaffey KW, Garg J. et al. Prevention of stroke and systemic embolism using the oral direct Factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: the ROCKET AF trial. N Engl J Med 2011; 365: 883-891.
3 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992.
4 The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
5 The EINSTEIN-PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med 2012; 366: 1287-1297.
6 Turpie AGG, Lassen MR, Eriksson BI. et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-453.
7 The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
8 Mega JL, Braunwald E, Mohanavelu S. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374: 29-38.
9 Giugliano RP. Edoxaban versus Warfarin in Patients with Atrial Fibrillation et al. N Engl J Med 2013; 363: 2093-104.
10 The Hokusai-VTE Investigators. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. N Engl J Med 2013; 369: 1406-1415.
11 Heidbuchel H, Verhamme P, Alings M. et al. Updated European Heart Rhythm Association (EHRA) Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17 (10) 1467-1507.
12 Pernod G, Albaladejo P, Godier A. et al. Working Group on Perioperative Haemostasis. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis 2013; 106 6-7 382-393.
13 Eisele R. et al. Perioperatives Gerinnungsmanagement bei oraler Antikoagulation. Chirurg 2014; 85: 513-519.
14 Giebl A, Gürtler K. Neue orale Antikoagulanzien in der perioperativen Medizin. Anaesthesist 2014; 63: 347-364.
15 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AMWF). S3-Leitlinie Prophylaxe der venösen Thromboembolie (VTE). AWMF-Registernr. 003/001 Klasse S3; 2015
16 von Heymann C, Koscielny J. Update: Patienten unter oraler Antikoagulation mit VKA oder NOAK - Perioperatives üBridging” oder ü„Switching”?. Anästh Intensivmed 2016; 57: 316-331.
17 Waurick K, Riess H, Van Aken H. et al. S1-Richtlinie: Rückenmarksnahe Regionalanästhesien und Thromboembolieprophylaxe/ antithrombotische Medikation. 3. überarbeitete Empfehlung der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin, Anästh Intensivmed 2014; 55: 464-492.
18 Sporbeck B, Bechara FG, Häfner HM. et al. S3-Leitlinie zum Umgang mit Antikoagulation bei Operationen an der Haut. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2015; 13: 346-357.
19 EMA - Dabigatran. www.ema.europa.eu/docs/ de_DE/document_library/EPAR Product_Information/human/000829/WC501657856059.pdf.
20 EMA - Rivaroxaban. http://www.ema.europa.eu/ docs/de_DE/document_library/EPAR_-_Product_Information/human/ 000944/WC500057108.pdf.
21 Pfizer - Apixaban. http://www.pfizer.de/filead min/produktdatenbank/pdf/Eliquis_5mg_FI_01.pdf.
22 EMA - Edoxaban. http://ec.europa.eu/health/ documents/communityregister/2015/20150619132091/anx_132091_de.pdf.
23 Beyer-Westendorf J, Förster K, Pannach S. et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden DOAC registry. Blood 2014; 124 (06) 955-962
24 Beyer-Westendorf J, Gelbricht V, Förster K. et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014; 35 (28) 1888-1896.
25 Steinberg BA, Peterson ED, Kim S, Thomas L, Gersh BJ, Fonarow GC, Kowey PR, Mahaffey KW, Sherwood MW, Chang P, Piccini JP, Ansell J. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Investigators and Patients. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation 2015; 131 (05) 488-494.
26 Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AGG. The XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016; 37 (14) 1145-1153.
27 Schulman S. et al. Perioperative Management of Dabigatran: A Prospective Cohort Study. Periop Dabigatran Study Group. Circulation 2015; 132 (03) 167-173.
28 Douketis JD. et al. Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. J Thromb Haemost 2016; 14 (01) 89-97.
29 Mallet L. et al. The challenge of managing drug interactions in elderly people. Lancet 2007; 370 (9582) 185-191.
30 Far E. et al. Validation of a transparent decision model to rate drug interactions. BMC Pharmacol Toxicol 2012; 13: 7.
31 bWHO. Adherence to long-term therapies. Evidence for action. ISBN 92 4 154599 2. 2003; 1-209.
32 NEHI (New England Healthcare Institute). (2009). Thinking Outside the Pillbox: A System-wide Approach to Improving Patient Medication Adherence for Chorionic Disease. http://www.nehi.net/ publications/44/thinking_outside_the_pillbox_a_systemwide_approach_to_improving_patient_medication_adherence_for_ chronic_disease. Last accessed October 2011..
33 Gräf M. Die volkswirtschaftlichen Kosten der Non-Compliance: Eine entscheidungsorientierte Analyse. Gesundheitsökonomie Band. 56. Bayreuth; P.C.O.-Verlag: 2007
34 Chatterjee S. et al. Treatment Discontinuations With New Oral Agents for Long-term Anticoagulation: Insights From a Meta-analysis of 18 Randomized Trials Including 101,801 Patients. Mayo Clinic Proceedings 2014; 89 (07) 896-907.
35 Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation?. J Thromb Haemost 2013; 11 (02) 390-394.
36 Beyer-Westendorf J. et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 2015; 17 (04) 530-538.
37 Gomes T. et al. Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med 2012; 172 (21) 1687-1689.
38 Gallagher AM. et al. Initiation and persistence of warfarin or ASA in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?. J Thromb Haemost. 2008. 06 09 1500-1506.
39 Shore S, Ho MP, Lambert-Kerzner A. et al. Sitelevel variation in and practices associated with dabigatran adherence. JAMA 2015; 313: 1443-1450.
40 Gorst-Rasmussen A, Skjøth F, Larsen TB. et al. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 2015; 13: 495-504.
41 Yao X. et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc 2016; 05 (02) 1-12.
42 Nieuwlaat R, Wilczynski N. et al. Interventions for enhancing medication adherence. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014; 11: 1-732.
43 Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M. et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood 2014; 124: 3692-3698.
44 Breuer G, Weiss DR, Ringwald J. New’ direct oral anticoagulants in the perioperative setting. Curr Opin Anaesthesiol 2014; 27: 409-419.
45 Koscielny J, Beyer-Westendorf J, von Heymann C, Braun J, Klamroth R, Lindhoff-Last E. et al. [Risk of bleeding and haemorrhagic complication with rivaroxaban--periprocedural management of haemostasis]. Hamostaseologie 2012; 32: 287-293.
46 Spannagl M, Bauersachs R, Debus ES, Gawaz M, Gerlach H, Haas S. et al. [Dabigatran therapy - perioperative management and interpretation of coagulation tests]. Hamostaseologie 2012; 32: 294-305.
47 Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M. et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Sub-study of the RE-LY trial. Thrombosis and haemostasis 2015; 113: 625-632.
48 Beyer-Westendorf J, Ebertz F, Forster K, Gelbricht V, Michalski F, Kohler C. et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thrombosis and haemostasis 2015; 113: 1247-1257.
49 Kessler P, Steinfeldt T, Gogarten W, Schwemmer U, Buttner J, Graf BM. et al. [Peripheral regional anesthesia in patients under general anesthesia: risk assessment with respect to parasthesia, injection pain and nerve damage]. Anaesthesist 2013; 62: 483-488.
50 Salazar DE. et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012; 107 (05) 925-936.
51 Mueck W. et al. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 2013; 76: 455-466.
52 Moore KT. et al. An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function. J Clin Pharmacol 2014; 54 (12) 1407-1420.
53 Lehr T. et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 2012; 52 (09) 1373-1378.
54 Stangier J. et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallelgroup, single-centre study. Clin Pharmacokinet 2010; 49 (04) 259-268.
55 Mendell J. et al. The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults. Clinical Drug Investigation. 2015; 35 (07) 447-453.
56 Chang M. et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol 2016; 56 (05) 637-645.